摘要
Abstract
Objective:To investigate the effect of Dapagliflozin in patients with type 2 diabetes mellitus(T2DM)complicated with chronic heart failure(CHF).Method:A total of 180 patients with T2DM complicated and CHF who admitted to Gansu Rehabilitation Center Hospital from January 2021 to December 2022 were selected as the study objects,and they were randomly divided into the experimental group and the control group according to the envelope method,90 cases in each group.The control group was treated with Metformin,while the experimental group was treated with Dapagliflozin.The clinical efficacy,cardiac function,blood glucose levels,serum soluble matrix lysin 2(ST2),growth differentiation factor-15(GDF-15),von Willebrand factor(vWF)levels were compared between two groups.Result:The total effective rate in the experimental group was 93.33%,which was higher than 83.33%in the control group,the difference was statistically significant(P<0.05);after 12 weeks of treatment,the left ventricular end-diastolic pressure and blood glucose of two groups decreased,the left ventricular end-systolic pressure and left ventricular shortening fraction increased,and the left ventricular end-diastolic pressure,2 h postprandial blood glucose and fasting blood glucose of the experimental group were lower than those of the control group,and the left ventricular end-systolic pressure and left ventricular shortening fraction were higher than those of the control group,the differences were statistically significant(P<0.05);after 12 weeks of treatment,the serum ST2,vWF and GDF-15 levels in two groups decreased,and those in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:In the treatment of T2DM complicated with CHF,Dapagliflozin has a significant effect,which helps to reduce serum ST2,GDF-15 and vWF levels,improve cardiac function,and promote blood glucose levels.关键词
2型糖尿病/生长分化因子-15/达格列净/血管性血友病因子/慢性心力衰竭Key words
Type 2 diabetes mellitus/Growth differentiation factor-15/Dapagliflozin/Vascular hemophilia factor/Chronic cardiac failure
